Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice

BACKGROUND: Sodium glucose co-transporter2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with canagliflozin on biochemical an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Nasiri-Ansari, Νarjes, Dimitriadis, Georgios K., Agrogiannis, Georgios, Perrea, Despoina, Kostakis, Ioannis D., Kaltsas, Gregory, Papavassiliou, Athanasios G., Randeva, Harpal S., Kassi, Eva
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6063004/
https://ncbi.nlm.nih.gov/pubmed/30049285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-018-0749-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars